trans-Tetrahydrofuran-3,4-diaminedihydrochloride | 137279-45-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: trans-Tetrahydrofuran-3,4-diaminedihydrochloride
• 英文别名: (3R,4R)-oxolane-3,4-diamine;dihydrochloride
• CAS: 137279-45-9
• 化学式: C4H12Cl2N2O
• 分子量: 175.05
• InChiKey: PJOPFTSMNUPXIB-RGVONZFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.49
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  61.3
• 氢给体数：
  4
• 氢受体数：
  3

文献信息

• FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
  申请人：Abbisko Therapeutics Co., Ltd.

  公开号：US20190270742A1

  公开（公告）日：2019-09-05

  Provided are an FGFR4 inhibitor having the structure of formula (I), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and can be widely used in the preparation of a drug for treating cancers, especially prostate cancer, liver cancer, pancreatic cancer, esophageal carcinomas, gastric cancer, lung cancer, breast cancer, ovarian carcinomas, colon cancer, skin cancer, glioblastomas or rhabdomyosarcomas, and is expected to be developed into a new generation of FGFR4 inhibitor drugs.

  提供一种具有结构式（I）的FGFR4抑制剂，以及其制备方法和用途。该化合物对FGFR4激酶活性具有非常强的抑制作用，并具有非常高的选择性，可以广泛用于制备用于治疗癌症的药物，特别是前列腺癌、肝癌、胰腺癌、食管癌、胃癌、肺癌、乳腺癌、卵巢癌、结肠癌、皮肤癌、胶质母细胞瘤或横纹肌肉瘤，并有望被开发成新一代的FGFR4抑制剂药物。
• FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
  申请人：Abbisko Therapeutics Co., Ltd.

  公开号：US10968220B2

  公开（公告）日：2021-04-06

  Provided are an FGFR4 inhibitor having the structure of formula (I), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and can be widely used in the preparation of a drug for treating cancers, especially prostate cancer, liver cancer, pancreatic cancer, esophageal carcinomas, gastric cancer, lung cancer, breast cancer, ovarian carcinomas, colon cancer, skin cancer, glioblastomas or rhabdomyosarcomas, and is expected to be developed into a new generation of FGFR4 inhibitor drugs.

  本发明提供了一种具有式(I)结构的FGFR4抑制剂及其制备方法和用途。该化合物对 FGFR4 激酶活性有很强的抑制作用，并具有很高的选择性，可广泛用于制备治疗癌症的药物，特别是前列腺癌、肝癌、胰腺癌、食管癌、胃癌、肺癌、乳腺癌、卵巢癌、结肠癌、皮肤癌、胶质母细胞瘤或横纹肌肉瘤，有望开发成新一代 FGFR4 抑制剂药物。